---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-007616"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-02-23T23:59:59+00:00"
generated_at: "2026-06-05T17:31:13.765642+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera closes $8M private placement of convertible preferred shares, warrants for up to $8M more

## Summary
- $8.0 million raised from Series B-1 Preferred at $1,000/share; warrants for additional $8.0 million upon milestone achievement and shareholder approval.
- Conversion price $0.7074; Series B-1 convertible into up to 9,310,677 common shares; warrants into 11,309,019 shares.
- Net proceeds for working capital and development of additional indications for Ameluz (actinic keratosis).
- Initial conversion of preferred shares into 2,516,785 common shares, increasing total outstanding to 5,089,413 common shares.
- Roth Capital Partners acted as placement agent; Rosalind Advisors led institutional investors.

## SEC filing metadata
- accession: 0001493152-24-007616
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-007616
- JSON: https://secwatch.observer/filing/0001493152-24-007616.json
- Plain text: https://secwatch.observer/filing/0001493152-24-007616.txt

## Key facts
- Governance Changes
  Biofrontera Inc.: Filed Certificate of Designation for Series B Preferred Stock, establishing rights, preferences, and limitations of three new series of preferred stock (effective 2024-02-20).
  - Change: charter amendment
  - Effective: 2024-02-20
  source text: on February 20, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 6,586 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock, 6,586 shares as Series B-2 Preferred Stock and 8,000 shares as Series B-3 Convertible Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm
- Material Agreements
  Biofrontera Inc. entered into Securities Purchase Agreement with accredited investors (Preferred Investors) valued at $8,000,000 (effective 2024-02-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited investors (Preferred Investors)
  - Value: $8,000,000
  - Effective: 2024-02-19
  source text: On February 19, 2024, the Company entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Preferred Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 6,586 shares of Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), and (iii) warrants (the “ Preferred Warrant ”) to purchase shares of Series B-3 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-3 Preferred Stock ”) for an aggregate offering price of $8.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.